PT in Focus: General Motors Company (NYSE:GM), Biogen Idec Inc. (NASDAQ:BIIB)


Wall Street sell-side research analysts covering General Motors Company (NYSE:GM) shares have recently provided various price target projections on where the stock might be going. According to them, the stock is expected to reach $36.75 on a consensus level within the next year, according to Zacks. The most bullish estimate sees the stock reaching $43 while the most conservative estimate stand at $31.

Zacks also gives an average broker rating based on the sell-side recommendations from the analysts who cover General Motors Company. They give the company shares an ABR of 2.38. This is based on the 12 analysts taken into consideration by Zacks.

Earnings Estimates for General Motors Company (NYSE:GM)

Currently, Wall Street is projecting that the firm will post $1.2 earnings per share. This consensus number is also derived from Zacks. For the most recent period which ended on 2016-09-30, General Motors Company's EPS was reported as $1.72. This created a “surprise factor” 19.44% due to being $0.28 apart from what Wall Street predicted. When actual numbers differ greatly from the consensus expectations, sharp movement in the stock price can often be seen in the hours or days following the report.

Investors will mark their calendars for 2017-02-01, the date when General Motors Company (NYSE:GM) are expected to release their quarterly results.

Research analysts covering Biogen Idec Inc. (NASDAQ:BIIB) are projecting that the shares reach $341.857 within the next 12-18 months.  This is the consensus number derived from the 14 analyst reports taken into consideration. The most bullish, or aggressive analyst target pins the projected price at $384, while the most bearish, or conservative analyst sees the stock reaching $283.

Broker Rating Update on Biogen Idec Inc. (NASDAQ:BIIB)

Zacks provides analysts with an Average Broker Rating (or ABR), basing it on sell-side recommendations. Shares of Biogen Idec Inc. (NASDAQ:BIIB) currently have an ABR of 1.53. This is based on a simplified 1 to 5 scale where 1 represents a Strong Buy and 5 a Strong Sell.  Moving to earnings estimates, for this current fiscal period, Wall Street analysts have projected that the company will post $5 earnings per share. This is the current Zacks consensus EPS which was calculated at the time of writing. Analysts will likely revise their estimates leading in to the actual results date.  

taking a look at the most recent period, which closed on 2016-09-30, Biogen Idec Inc. reported EPS of $5.19 for a surprise factor of 4.01%, calculated by being $0.2 away from analyst projections.

Investors will be marking their calendars for 2017-01-25, when the company is planning to release their quarterly results.